en · de · es · pt
melanotan-2-notes.peptides7501.com › Info › Identity And Chemical Background — Quick Reference

Identity And Chemical Background — Quick Reference

By Editorial Desk · published 2025-11-09 · last reviewed 2025-12-26 · Info

The short version of alpha-MSH fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-12-26 and is reviewed periodically as new material appears.

Identity and Chemical Background

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Regulation, Literature and Verification

Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.

Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Free base; salt forms differ
Molecular weightApproximately 1024 g/molCalculated for the free base
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
SolubilitySoluble in water and polar solventsPoorly soluble in non-polar solvents
Typical storage-20 degrees Celsius, dry, protected from lightRefers to the solid form

Melanotan II Background and Mechanism

Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.

Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.

Related pages on this site

Storage, Stability, and Analysis

Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.

Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.

Notes from published material

Mn(CO)5Cl + AlCl3 + CO → [Mn(CO)+6][AlCl−4] The use of strong acids succeeded in preparing gold carbonyl cations such as [Au(CO)2]+, which is used as a catalyst for the carbonylation of alkenes. The cationic platinum carbonyl complex [Pt(CO)4]2+ can be prepared by working in so-called superacids such as antimony pentafluoride. Although CO is considered generally as a ligand for low-valent metal ions, the tetravalent iron complex [Cp*2Fe]2+ (16-valence electron complex) quantitatively binds CO to give the diamagnetic Fe(IV)-carbonyl [Cp*2FeCO]2+ (18-valence electron complex).

== Pull down time == The pull down time is defined as the necessary time to cool down the ULT freezer from ambient temperatures to the selected temperature of −80 to −86 °C (−112 to −123 °F). The time strongly depends on the type of insulation, the efficiency of the compressor system as well as the installed metal shelves within the freezer. At the start of the twenty-first century, ULT freezers were able to cool down within 3 to 5 hours. Warm up time is typically 1/8 °C per minute.

=== Medicated fishfood === Medicated fishfood is a safe and effective method to deliver medication to fish. One advantage is that medicated food does not contaminate the aquatic environment and also, unlike bath treatments, does not negatively affect fish, filtration and algae growth in the aquarium. The parasites will get treated spot on by medicated food, because the fish is ingesting it.

=== Iran === The celebration of Persian New Year, or Nowruz, dating back over 3,000 years, marks the advent of spring, and tulips are used as a decorative feature during the festivities. The 12th century Persian tragic romance, Khosrow and Shirin, similar to the tale of Romeo and Juliet, tells of tulips sprouting where the blood of the young prince Farhad spilt after he killed himself upon hearing the (deliberately false) story that his true love had died. The tulip was a topic for Persian poets from the thirteenth century. The poem Gulistan by Musharrifu'd-din Saadi, described a visionary garden paradise with "The murmur of a cool stream / bird song, ripe fruit in plenty / bright multicoloured tulips and fragrant roses...". Tulips have featured in the poems of Simin Behbahani. The tulip is the national symbol for martyrdom in Iran (and Shi'ite Islam generally), and has been used on postage stamps and coins. It was common as a symbol used in the 1979 Islamic Revolution, and a red tulip adorns the flag redesigned in 1980. The sword in the centre, with four crescent-shaped petals around it, create the word "Allah" as well as symbolising the five pillars of Islam. The tomb of Ayatollah Ruhollah Khomeini is decorated with 72 stained glass tulips, representing 72 martyrs who died at the Battle of Karbala in 680 CE. It was also used as a symbol on billboards celebrating casualties of the 1980–1988 war with Iraq.

Sources: en.wikipedia.org

Further detail

The term diabetes is derived from the Ionic for 'siphon', meaning "to pass or run through". It reflects the dominant notion at the time that fluids consumed by the diabetic patient passed through the body unchanged, as if flowing through a tube or siphon. A number of conflicting accounts exist as to the first use of this term, placing the originator as either Apollonius of Memphis (fl. 3rd century BC), Demetrius of Apamea (fl. 100 BC), or Aretaeus of Cappadocia (fl. early 2nd century AD). In-depth probes of Greek etymology agree that the term came from Demetrius of Apamea, C. L. Gemmill (1972) states:Caelius Aurelianus prepared a Latin version of the works of Soranus. In the index of the Drabkin edition there is a subject heading "Diabetes," but on examination of the text this section could not be found (footnote 3, p. 776) except for a short paragraph. In this paragraph Caelius quotes Apollonius of Memphis as separating two forms of dropsy, one marked by retention of fluid and the other by the inability to retain fluid; the patient discharges whatever he drinks as if it were passed through a pipe. Apollonius lived in the second half of the third century B.C. Caelius Aurelianus continues by stating that Demetrius of Apamea distinguishes this disease from dropsy in which any fluid that is drunk is discharged as urine. Demetrius calls this condition diabetes. The time of Demetrius of Apamea is given as the first century B.C. None of his works have come down to us; we have only quotations in later authors.

=== China === In China, the use of IUDs by state health services was part of the government's efforts to limit birth rates. From 1980 to 2014, 324 million women were inserted with IUDs, in addition to the 107 million who had tubal ligation. Until the mid-1990s, the state-preferred IUD was a stainless steel ring, which had a higher rate of complications compared to other types of IUD. It gave rise to the idiom shànghuán (上环), meaning "insert a loop". Since then, IUDs include T and V shapes, the former being the most common and easiest to remove.

On August 21, 2018, In-N-Out announced plans to open a location in the Willamette Valley in Keizer. This was the company's northernmost location. On November 30, 2017, the company announced plans to build a production facility and distribution center in Colorado Springs, ahead of an expansion into Colorado, which is scheduled to be completed in 2021. The first Colorado locations opened in Colorado Springs and Aurora on November 20, 2020. In-N-Out received approval for a new distribution center to open in Chino, California, in 2020, taking some of the load off the long-standing Baldwin Park distribution center. The center opened later that year. On November 24, 2020, In-N-Out signaled that it was in the early stages of opening a store in Idaho. The first store in the state opened in Meridian in December 2023. In-N-Out later expressed interest in opening additional stores in Boise and Nampa, as well as a second location in Meridian. The company pursued various locations around Portland, Oregon, which were rejected or stalled due to development issues; a location in Ridgefield, Washington, the first in Washington state, was announced in 2024. The location in Ridgefield, Washington opened on August 20, 2025, becoming the first in the state. A second Washington state location opened on April 23, 2026 in Vancouver, Washington. A location in Hillsboro, Oregon is expected to open in June 2026.

== Publication == In July 2016, Hillbilly Elegy was popularized by an interview with Vance in The American Conservative. The volume of requests briefly disabled the website. Halfway through August, The New York Times wrote that the title had remained in the top ten Amazon bestsellers since the interview's publication. Vance has credited his Yale contract law professor Amy Chua as the "authorial godmother" of the book, as she persuaded him to write the memoir.

== See also == Arnault Tzanck Blood transfusion in Sri Lanka Young blood transfusion, a pseudoscientific practice involving the transfusion of blood taken from young donors to older recipients that is claimed to have health benefits Transdifferentiation AIDS

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 a naturally occurring substance?

No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.

How is melanotan-2 distinguished from afamelanotide?

Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.

Why does the compound appear in tanning-related discussion?

Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.

Has it been tested in clinical trials?

Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.

Network